Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Neostem Inc . (NASDAQ:LSTA) stock has reached a 52-week low, touching down at $2.15, as the company grapples with a challenging market environment. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 6.16 and holds more cash than debt on its balance sheet. This latest price point marks a significant downturn for the biotechnology firm, which has seen its stock value decrease by 30.54% over the past year, with YTD returns down 20.13%. Investors are closely monitoring Neostem’s performance, as the company navigates through the headwinds that have led to this low, with hopes for a strategic turnaround that could potentially rejuvenate its market position and investor confidence. While current market sentiment is bearish, InvestingPro analysis suggests the stock may be undervalued, with analyst price targets ranging from $15 to $21. Discover more insights and 6 additional ProTips with an InvestingPro subscription, including detailed analysis in the comprehensive Pro Research Report.
In other recent news, Lisata Therapeutics Inc. reported its fourth-quarter earnings for 2024, revealing a total revenue of $1 million, primarily from an upfront license fee with KUVA Labs. The company managed to reduce its operating expenses by 8.9% year-over-year, ending with a net loss of $20 million, a slight improvement from the previous year’s $20.8 million loss. Lisata maintains a cash reserve of $31.2 million, expected to support operations into the second quarter of 2026. The company continues its focus on developing setepatide, a treatment for advanced solid tumors, with ongoing trials and regulatory advancements. Analysts have not provided recent upgrades or downgrades for Lisata Therapeutics, but the company remains committed to its strategic development plans. Lisata anticipates a "data-rich" year in 2025 with potential progression for its pancreatic cancer treatment. The firm is also exploring setepatide’s therapeutic potential in other areas, such as endometriosis, through preclinical investigations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.